Cereno Scientific expands patent protection for drug candidate CS1 through its second patent family
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that drug candidate CS1’s second patent family has obtained a newly issued patent in Japan. This strengthens and broadens the intellectual property rights (IPR) for Cereno’s Phase II drug candidate CS1, which is being developed for the treatment of rare disease pulmonary arterial hypertension (PAH).“I am pleased to share that we are securing further IPR for drug candidate CS1 in the key market Japan, which is one of the largest global